Patents Examined by Thomas Heard
-
Patent number: 8906863Abstract: This invention provides a peptide/nucleic acid composition for oral/mucosal, dual-modal activation of immune protection systems.Type: GrantFiled: September 1, 2011Date of Patent: December 9, 2014Assignee: The Regents of the University of CaliforniaInventors: R. Holland Cheng, Li Xing
-
Patent number: 8906862Abstract: This invention provides a peptide/nucleic acid composition for oral/mucosal, dual-modal activation of immune protection systems.Type: GrantFiled: August 29, 2011Date of Patent: December 9, 2014Assignees: The Regents of the University of California, National Institute of Infectious Disease, Tsukuba Primate Research Center, National Institue of Biomedical InnovationInventors: R. Holland Cheng, Li Xing, Tatsuo Miyamura, Yasuhiro Yasutomi, Tian-Cheng Li, Naokazu Takeda
-
Patent number: 8906849Abstract: The present invention provides novel Pancreatic Polypeptide Family (“PPF”) polypeptides and methods for their use.Type: GrantFiled: April 8, 2013Date of Patent: December 9, 2014Assignees: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LPInventors: Odile Esther Levy, Carolyn M. Jodka, Soumitra S. Ghosh, David G. Parkes, Richard A. Pittner, Lawrence J. D'Souza, John S. Ahn, Kathryn S. Prickett, Jonathan David Roth, Sean H. Adams
-
Patent number: 8877709Abstract: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.Type: GrantFiled: January 2, 2014Date of Patent: November 4, 2014Assignee: Yeda Research and Development Co., Ltd.Inventors: Yoram Shechter, Matityahu Fridkin, Haim Tsubery
-
Patent number: 8871904Abstract: The invention relates to compounds and processes useful for the preparation of protease inhibitors, particularly serine protease inhibitors. The protease inhibitors are useful for treatment of HCV infections.Type: GrantFiled: February 14, 2013Date of Patent: October 28, 2014Assignee: Vertex Pharmaceuticals IncorporatedInventors: Gerald J. Tanoury, Minzhang Chen, John E. Cochran, Adam Looker, Valdas Jurkauskas
-
Patent number: 8865656Abstract: ?-Hairpin peptidomimetics of the general formula Cyclo(-Xaa1-Xaa2-Xaa3-Cys4-Xaa5-Xaa6-Xaa7-Xaa8-Arg9-Tyr10-Cys11-Xaa12-Xaa13-Xaa14-Xaa15-Xaa16-), disulfide bond between Cys4 and Cys11, and pharmaceutically acceptable salts thereof, with Xaa1, Xaa2, Xaa3, Xaa5, Xaa6, Xaa7, Xaa8, Xaa12, Xaa13, Xaa14, Xaa15 and Xaa16 being amino acid residues of certain types which are defined in the description and the claims, have CXCR4 antagonizing properties and can be used for preventing HIV infections in healthy individuals or for slowing and halting viral progression in infected patients; or where cancer is mediated or resulting from CXCR4 receptor activity; or where immunological diseases are mediated or resulting from CXCR4 receptor activity; or for treating immunosuppression; or during apheresis collections of peripheral blood stem cells and/or as agents to induce mobilization of stem cells to regulate tissue repair.Type: GrantFiled: May 7, 2009Date of Patent: October 21, 2014Assignee: Polyphor AGInventors: Daniel Obrecht, Frank Gombert, Alexander Lederer, Barbara Romagnoli, Christian Bisang
-
Patent number: 8865654Abstract: An eyedrop containing a peptide having an amino acid sequence represented by Ser-Ser-Ser-Arg (“SSSR”), or a pharmacologically acceptable salt thereof; and a peptide having an amino acid sequence represented by Phe-Gly-Leu-Met-NH2 (“FGLM”), or a pharmacologically acceptable salt thereof. The concentration ratio between SSSR or a pharmacologically acceptable salt thereof and FGLM or a pharmacologically acceptable salt thereof is between 1/15 and 1/50. The concentration of SSSR or a pharmacologically acceptable salt thereof is between 0.001% and 0.3% (w/v) and the concentration of FGLM or a pharmacologically acceptable salt thereof is between 0.015% and 1.5% (w/V). The pH of the eye drop is maintained between 2.5 and 6.5.Type: GrantFiled: September 24, 2010Date of Patent: October 21, 2014Assignee: Santen Pharmaceutical Co., Ltd.Inventors: Takahiro Nakamura, Yuichiro Nakada, Takashi Nagano, Masatsugu Nakamura
-
Patent number: 8853161Abstract: The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.Type: GrantFiled: September 27, 2011Date of Patent: October 7, 2014Assignee: Novo Nordisk A/SInventors: Shawn DeFrees, David A. Zopf, Robert J. Bayer, David James Hakes, Caryn Bowe, Xi Chen
-
Patent number: 8846617Abstract: The present invention relates to the use of compounds selected from the group consisting of Lys-(D)Pro-Thr, N-acyl Lys-(D)Pro-Thr, C-amide Lys-(D)Pro-Thr, and C-esters of Lys-(D)Pro-Thr; or a pharmaceutically acceptable salt of said compound fort he treatment of inflammatory disorders. The invention also relates to the use of ?MSH for inducing tolerance.Type: GrantFiled: July 16, 2011Date of Patent: September 30, 2014Inventor: Thomas Luger
-
Patent number: 8846619Abstract: This invention provides heme-containing peptides capable of binding molecular oxygen at room temperature. These compounds may be useful in the absorption of molecular oxygen from molecular oxygen-containing atmospheres. Also included in the invention are methods for treating an oxygen transport deficiency in a mammal.Type: GrantFiled: March 4, 2010Date of Patent: September 30, 2014Assignee: The Trustees of the University of PennsylvaniaInventor: P. Leslie Dutton
-
Patent number: 8835392Abstract: The present invention relates to peptide-mimetic compounds, the synthesis and use thereof fort he inhibition of proteasomes and the induction of apoptosis in tumor cells. The present invention furthermore relates to pharmaceutical compositions comprising the compounds and the use of the compounds for a treatment of diseases, in particular cancer and neurodegenerative diseases.Type: GrantFiled: March 3, 2006Date of Patent: September 16, 2014Assignees: Technische Universität, Charité—Universitätsmedizin BerlinInventors: Boris Schmidt, Sumaira Umbreen, Hannes Braun, Peter-Michael Kloetzel, Ulrike Kuckelkorn
-
Patent number: 8828930Abstract: The present invention relates to macrocyclic compounds of Formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.Type: GrantFiled: July 27, 2010Date of Patent: September 9, 2014Assignee: Merck Sharp & Dohme Corp.Inventors: Nigel J. Liverton, John A. McCauley, Michael T. Rudd
-
Patent number: 8822421Abstract: The instant invention provides amino acid sequences competing with E2F for DNA binding. Methods of using said amino acid sequences for treatment of hormone-refractory prostate cancer are also provided.Type: GrantFiled: October 14, 2011Date of Patent: September 2, 2014Assignee: Rutgers, The State University of New JerseyInventors: Joseph R. Bertino, Debabrata Banerjee, Tamara Minko, Olga B. Garbuzenko, Xiaoqi Xie, John E. Kerrigan, Emine E. Abali, Kathleen W. Scotto
-
Patent number: 8822512Abstract: The disclosure features crystalline tripeptide keto epoxide compounds, methods of their preparation, and related pharmaceutical compositions.Type: GrantFiled: September 20, 2011Date of Patent: September 2, 2014Assignee: Onyx Therapeutics, Inc.Inventors: Pasit Phiasivongsa, Louis C. Sehl
-
Patent number: 8815796Abstract: The present invention discloses the structure, preparation methods and uses of a series of novel polyheterocyclic based compounds (Ia-Ib and IIa-IIb) that are highly effective for inhibiting hepatitis C virus (HCV): where the structural variables are defined herein. The present invention is also provides a method of treating HCV infection by the polyheterocyclic based HCV inhibitory compounds, compositions and therapeutic methods.Type: GrantFiled: September 3, 2013Date of Patent: August 26, 2014Assignee: AB Pharma Ltd.Inventor: Zheng-Yun James Zhan
-
Patent number: 8809266Abstract: The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.Type: GrantFiled: March 11, 2013Date of Patent: August 19, 2014Assignee: Gilead Sciences, Inc.Inventors: Aesop Cho, Michael O'Neil Hanrahan Clarke, Choung U. Kim, John O. Link, Hyung-jung Pyun, Xiaoning C. Sheng, Qiaoyin Wu
-
Patent number: 8809264Abstract: The present invention relates to compounds, including compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: GrantFiled: June 26, 2007Date of Patent: August 19, 2014Assignee: Enanta Pharmaceuticals, Inc.Inventors: Deqiang Niu, Dong Liu, Joel D. Moore, Guoyou Xu, Ying Sun, Yonghua Gai, Datong Tang, Yat Sun Or, Zhe Wang
-
Patent number: 8809267Abstract: The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.Type: GrantFiled: July 1, 2013Date of Patent: August 19, 2014Assignee: Gilead Sciences, Inc.Inventors: Jeromy J. Cottell, John O. Link, Scott D. Schroeder, James Taylor, Winston C. Tse, Randall W. Vivian, Zheng-Yu Yang
-
Patent number: 8796218Abstract: A method for preparing a biologically active complex, said method comprising a recombinant protein having the sequence of ?-lactalbumin, such as human ?-lactalbumin or a fragment thereof but which lacks intra-molecular disulfide bonds, and oleic acid, and process for preparing this are described and claimed. The recombinant protein suitably has cysteines found in the native protein changed to other amino acids, such as alanine. Improvements in recombinant expression, process rationalisation and yields of biologically active complexes, as well as the complexes obtained are also described and claimed.Type: GrantFiled: January 8, 2010Date of Patent: August 5, 2014Assignee: Hamlet Pharma ABInventors: Catharina Svanborg, Kenneth Hun Mok, Ann-Kristin Mossberg, Jenny Petterson-Kastberg
-
Patent number: 8791236Abstract: A method for selectively acylating an amino group in a peptide or protein which has two or more reactive nucleophilic functional groups is described.Type: GrantFiled: January 28, 2014Date of Patent: July 29, 2014Assignee: Novo Nordisk A/SInventors: Caspar Christensen, Rune Severinsen, Anders Klarskov Petersen, Steffen Kidal, Claus U. Jessen, Peter Madsen, Henrik Valore, Tina Moeller Tagmose, Jan Lindy Soerensen